The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
- 21 March 2022
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 171, 1-6
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 21 references indexed in Scilit:
- Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in HumansCirculation, 2016
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)JACC, 2014
- A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and AtherosclerosisInternational Journal of Rheumatology, 2012
- Mechanisms of Lipoprotein(a) PathogenicityArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary DiseaseNew England Journal of Medicine, 2009
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasmaJournal of Lipid Research, 2008
- Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a)Circulation, 2004
- Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromesJACC, 2003
- Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosisBlood, 2001